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Background: A diagnosis of diabetes mellitus types 1 or 2 doubles the odds of a comorbid depressive disorder.
The combined diseases have a wide range of adverse outcomes, such as a lower quality of life, poorer diabetes
outcomes and increased healthcare utilisation. Diabetes patients with depression can be treated effectively with
psychotherapy, but access to psychological care is limited. In this study we will examine the efficacy and
cost-effectiveness of a newly developed web-based intervention (GET.ON Mood Enhancer Diabetes) for people with
diabetes and comorbid depressive symptoms.
Methods/Design: A two-arm randomised controlled trial will be conducted. Adults with diabetes (type 1 or type 2)
with increased depression scores (> 22 on the German version of the Center for Epidemiological Studies Depression
Scale (CES-D)) will be included. Eligible participants will be recruited through advertisement in diabetes patient
journals and via a large-scale German health insurance company. The participants will be randomly assigned to either a
6-week minimally guided web-based self-help program or an online psychoeducation program on depression. The
study will include 260 participants, which will enable us to detect a statistically significant difference with a group effect
size of d = 0.35 at a power of 80% and a significance level of p = 0.05. The primary outcome measure will be the level
of depression as assessed by the CES-D. The secondary outcome measures will be: diabetes-specific emotional distress,
glycaemic control, self-management behaviour and the participants’ satisfaction with the intervention. Online
self-assessments will be collected at baseline and after a 2 months period, with additional follow-up measurements 6
and 12 months after randomisation. The data will be analysed on an intention-to-treat basis and per protocol. In
addition, we will conduct an economic evaluation from a societal perspective.
Discussion: If this intervention is shown to be cost-effective, it has considerable potential for implementing
psychological care for large numbers of people with diabetes and comorbid depression in routine practice and
improve health outcomes.
Trial registration: German Clinical Trial Register (DRKS): DRKS00004748.
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Diabetes is highly prevalent. The International Diabetes
Federation (IDF) estimates that in 2012, more than 371
million people worldwide were adversely affected by dia-
betes. It is estimated that 5.2 million people in Germany
suffer from diabetes [1]. A meta-analysis found that ap-
proximately 11% of all people with diabetes, that were
assessed through standardised diagnostic interviews, suf-
fered from depression. However, 31% of all people with
diabetes reported themselves as depressive when
assessed through self-report questionnaires [2]. In com-
parison to the general population, a diagnosis of diabetes
type 1 or type 2 doubles the odds of a comorbid depres-
sive disorder [2]. The combination of diabetes and de-
pression is associated with poor mental health and
harmful medical outcomes. People affected by comorbid
depression exhibit lower quality of life [3,4], poorer
adherence to diabetes self-care practises [5], worse gly-
caemic control [6] and greater risk of diabetes-related
complications [7]. Furthermore, comorbid depression in
diabetes is associated with excess mortality [8,9]. Studies
have shown that indirect and direct health care costs are
greater among adults with diabetes and depression com-
pared with adults with diabetes only [10-13].
Psychotherapy has been demonstrated to be as effect-
ive for people with diabetes and co-morbid depression
as for those without diabetes [14,15]. However, depres-
sion is poorly recognised in general [16] and depression
in diabetes is often undetected and untreated [17]. The
reasons are manifold, for example due to the overlap
of the symptoms of diabetes and depression, depression
is not always diagnosed [18,19], or due to perceived
stigmatisation of depression [20]. Using the Internet to
provide guided self-help interventions may help to over-
come some of the limitations of traditional treatment
services. The Internet exhibits anonymity and time-
independent access to treatment at low costs [21,22].
Meta-analyses have shown that web-based interven-
tions are effective for treating mental disorders such as
depression, anxiety or problem drinking [23-29] and
may be successfully implemented in routine practice
[30,31]. There are few web-based treatment studies for
comorbid disorders, but the results are promising
[32,33]. Van Bastelaar et al. (2011) conducted a study to
test the efficacy of a web-based diabetes-specific cogni-
tive behavioural therapy (CBT) intervention for persons
with diabetes and depression. They showed that the
web-based CBT program was efficacious in reducing
depressive symptoms in persons with diabetes type 1 or
type 2 (effect size d = 0.29) [32]. Moreover, a secondary
analysis found that clinical severity was not a sig-
nificant effect modifier [34]. Thus, web-based in-
terventions may be effective for people with diabetes
and comorbid sub-threshold or major depression(according to Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV)). This result aligns with the
meta-analysis by Andrews and colleagues about the poten-
tial of web-based interventions for treating severe mental
depression and anxiety [26].
Non-compliance and low adherence to physical treat-
ments or medication regiments are common problems
among people with diabetes [35], people with depres-
sion [36,37] and participants in web-based interven-
tions in general [38]. As van Bastelaar et al. [32] noted,
it is important to consider ways to minimise attrition
rates.
After considering the findings of van Bastelaar et al.
[32,34,39,40], we developed a minimally guided, diabetes-
specific web-based intervention with mobile phone support
to reduce depressive symptoms in the German speaking
population of diabetes patients. Subsequently, we will de-
termine whether the findings of van Bastelaar et al. [32]
can be replicated and whether short-term improvement
can be sustained in the long-term. We hypothesise that the
intervention group (IG), which will have access to the on-
line program GET.ON Mood Enhancer Diabetes (GET.ON
M.D.), will have significantly lower levels of depressed
mood than the control group (CG).
Web-based depression interventions appear to be
cost-effective for the general population as shown in a
small number of studies [41-44]. Although, a web-based
diabetes-specific intervention has shown to be effective
in reducing depressive symptoms, it is unclear whether
it is also cost-effective [32]. Hence, the present trial will
evaluate the economic impact of GET.ON M.D.. We
hypothesise that from a societal perspective, the GET.ON.
M.D. will be a cost-effective program for reducing depres-
sive symptoms of people with diabetes in comparison
to the control group.
Methods/Design
Study design
This study is designed as a randomised controlled trial
with two parallel groups. The IG will receive access to
the diabetes-specific, web-based online program (GET.
ON M.D.). The CG will receive general online psy-
choeducation about depression. Moreover, the CG will
have the opportunity to work with an unguided version
of the online program 12 months after baseline assess-
ment. The participants in both conditions will have
unrestricted access to treatment as usual during the
study.
Measurement points are scheduled equally for both
groups, at baseline and 8 weeks after randomisation. In
addition, there will be follow-up measurements 6 and 12
months after randomisation (Figure 1).
This study was approved by the Psychology Ethics Com-
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Figure 1 Study flow.
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Firstly, we will advertise the study in German journals
for people with diabetes. Secondly, we cooperate with a
large-scale German health insurance company: insurants
with diabetes will be informed via post about the possi-
bility of participating in this study. Furthermore, we will
contact large-scale diabetes patients organisations with
the request to inform their members about our study on
their websites. In addition, the study will be advertised
on social networks such as Facebook and Twitter.
The recruitment message for the study focuses on the
opportunity for people with diabetes mellitus (type 1 or
type 2) to help reduce depression. Recruitment is still
ongoing (start March 2013) with a total recruitment
time of 8 months.
Study procedures
The open access website (https://geton-training.de) con-
tains detailed information about the study. Interested
visitors may leave their email addresses on this website.
Afterwards, they will be registered in a secured web-
based platform and invited for an online screening. Thepeople who do not pass the screening will receive an ex-
planation for their exclusion along with the German pa-
tient guidelines for depression [45] via email. The people
who report suicidal ideation will receive an email with
the advice to seek professional help and detailed infor-
mation on available services. The participants who pass
the screening will be asked for informed consent via
email and will have to fill out a baseline questionnaire.
These participants will also be invited to complete the
Structured Clinical Interview (SCID-I for DSM IV, by
telephone) [46]. The SCID is used to assess whether the
included participants have major or minor depression at
baseline and whether they have had episodes of depres-
sion in the past. The SCID also includes a suicide proto-
col that enables us to identify people who are currently
suffering from suicidal ideation. The telephone SCID is
comparable to a face-to-face interview [47] and adminis-
tered by a trained interviewer. After the telephone inter-
view, the participants will be randomised.
To increase the probability that the participants will
complete the follow-up procedure (8 weeks, 6 months and
12 months after baseline), they are offered a monetary
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the completion of all follow-up surveys). Payment will be
arranged after each complete questionnaire has been
received.
Study population
This study focuses on adults with diabetes mellitus type
1 or type 2 and depressive symptoms.
The following inclusion criteria apply
Aged 18 or above; German language skills; presence
of diabetes mellitus type 1 or type 2 diagnosed more
than 3 months prior to the study; depressed mood, as in-
dicated by a value of 23 or higher [48,49] on the Center
for Epidemiological Studies Depression Scale (CES-D);
access to the Internet and an email address.
The following exclusion criteria apply
A risk of suicide as measured by item 9 of the Beck
Depression Inventory II (BDI II) (value > 1) [50]; a risk
of suicide as measured by the SCID [46] and an attached
suicide protocol; current psychotherapeutic treatment or
being present on a waiting list for such treatment; or
pregnancy.
Sample size
Informed by previous studies [25,32], the sample size is
based on the expected difference in the primary outcome
(CES-D) between the intervention group and the control
group at post-test. This sample size provides 80% power
to detect a mean difference of d = 0.35 in the effect sizes
for the primary outcome (alpha = 0.05, two-tailed test; cal-
culated using Power Analysis and Sample Size Software
(PASS 12)). We will need 130 participants per group;
hence a total of 260 participants will be included.
Randomisation
An automated, web-based randomisation program (ran-
domisation.eu) will assign the participants to either the
intervention or the control group in a ratio of 1:1.
Description of the two groups
Intervention group
The GET.ON M.D. program consists of 6 minimally
guided online sessions. Each session has an average dur-
ation of 45 minutes and includes homework assignments
and a mood diary. The participants will be advised to work
on one or two sessions each week. Guidance will be pro-
vided by graduate students and psychologists (trainers).
Trainers are supervised by an experienced clinical psych-
ologist. The communication between the participants and
the trainers will take place via the internal messaging func-
tion on the GET.ON M.D. platform.The primary task of the trainer is to reflect on the proc-
essed sessions to increase the participants’ motivation and
adherence. The trainer will spend approximately three
hours in total with each participant. The web-based pro-
gram is designed to be flexible, and the participants will
be able to follow the program on the Internet – also on a
tablet or on a mobile phone. An integrated read-aloud
function will allow the participants to follow the audio-
narration of each session.
Intervention content
GET.ON M.D. is based on two main evidence-based
components: systematic behavioural activation [51] and
problem solving [52]. In addition, the program also
focuses on relevant diabetes-specific topics, including
worries about diabetes complications, physical training,
blood glucose, the physician-patient relationship and
sexuality [53,54]. The program was developed by con-
solidating our body of research, clinical experience and
input from a diabetes medical specialist (Table 1).
Psychoeducation (session 1)
The first session consists of psychoeducation [55]. The
participants are informed that diabetes and depression
are linked and can impact each other. In two videos,
they are provided psychoeducational information, and
they receive an overview of the whole program. After
defining their goals concerning depression and diabetes,
the participants choose a first positive activity for the
next day.
Behavioural activation (sessions 2 and 5)
The concept of behavioural activation is introduced with
a video. The participants are familiarised with the con-
nection between pleasant activities and mood. With the
help of examples, the participants create an individual
list of activities. Based on the principles of action plan-
ning and coping planning, the participants schedule
pleasant activities for a few days [51]. Starting with ses-
sion 2, this scheduling component is integrated into each
session.
In session 5, the key focus is on physical activity. Based
on the transtheoretical model of health behaviour
change [56], the participants can reflect on their own
stage of change and receive adapted information and
tasks.
Problem solving (sessions 3 and 4)
Throughout sessions 3 and 4, the main focus is on prob-
lem solving [52]. After listing experienced problems, the
participants are prompted to classify their problems as
solvable or unsolvable. Following a video, the partici-
pants become familiar with a six-step plan to handle
solvable problems. Next, they are encouraged to apply
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ticipants retrospectively review their plans and choose to
either continue to work on the specific problem or start
to work on a new one. In addition, they learn techniques
to reduce rumination on unsolvable problems.Plan for the future (session 6)
In the last session, the participants assess whether they
have seen improvements in mood. They can learn about
additional ways to get help, if needed. In addition, the
participants reflect on which techniques suit them, and
are encouraged to make a plan for the future. At the
end, they write a letter to themselves about what they
want to achieve during the next four weeks.Optional sessions and booster session
The participants are offered two optional sessions
(healthy sleep and coping with obesity) that are available
at the end of sessions 2 through 5. It is known that in-
somnia is a predictor and a symptom of depression [57].
The sleep session offers information on the principles of
sleep hygiene, sleep restriction and stimulus control
[58]. There is also a relationship between obesity and de-
pression [59]. In particular, people with diabetes type 2
often suffer from obesity [60]. The aim of this session is
to cope with the psychological consequences of obesity,
for example frustration, feelings of self-blame and guilt.Four weeks after finishing the intervention, the partici-
pants have the opportunity to work on an optional
booster session. The aim of this session is to evaluate
progress and to strengthen their newly acquired skills.
Improving efficacy and adherence
Taking into account that non-compliance presents as a
problem in web-based programs [38], in many depressed
people [36,37] and people with diabetes [35], we devel-
oped two ways to increase the number of sessions com-
pleted by the intervention group.
Improving efficacy and adherence I: text message coach
Preliminary results have shown that mobile phone-based
interventions and mobile phone supportive messages
have the potential to improve psychological wellbeing
and decrease stress or depression [61]. A pilot study
demonstrated that daily text messaging, as a supplement
to face-to-face CBT, is feasible and acceptable to pa-
tients. Positive experiences with the text messages were
reported by 65% of the participants [62]. Studies have
also indicated that text messages about diabetes self-
management can also lead to benefits in some cases
[63,64]. The participants in this study will have the op-
portunity to apply for a standardised text message coach:
they will receive daily text messages to support their
efforts to integrate the techniques they learn within the
program into everyday life. The text messages address
four different areas: behavioural activation, problem
solving, diabetes and motivation enhancement.
Improving efficacy and adherence II: phone call
Clarke et al. (2005) have demonstrated that reminders
(by telephone or postcards) are a pivotal factor in effect-
iveness and attrition [65]. In the GET.ON M.D. study, a
participant who does not complete a session within one
week will receive a reminder email from his or her per-
sonal trainer. If a participant does not log in to the pro-
gram during the next seven days after receiving this
reminder, he or she will receive a phone call from his or
her trainer.
The aim of this call is both to motivate the participant
to proceed with the training and to identify the exact
reasons for not logging in (e.g. forgetfulness, technical
problems, lack of interest).
Control group - psychoeducation
The CG will have access to online psychoeducation based
on the German S3-Guideline/National Disease Manage-
ment Guideline “Unipolar Depression” [45]. Psychoedu-
cation is helpful in reducing depressive symptoms [55].
It informs the participants about the nature of depression
including information about symptoms and sources of help.
After the last measurement point (12 months after
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the GET.ON M.D. program.Outcome assessment
For an overview of the assessments at baseline, after
treatment and during the follow-up phase see Table 2.Primary outcome measures
The primary outcome is the level of depression, which is
measured by the CES-D, a well-validated self-report de-
pression questionnaire that will be administered online
[48,49]. The CES-D consists of 20 items that are answered
on a 4-point Likert scale; the total score ranges between 0
and 60. The internal consistency is reported to be α = 0.89,
and the split-half reliability is r = 0.91 [48].Table 2 Overview of the assessments
T0 T1 T2 T3 T4
Measurements for the efficacy evaluation
Center for epidemiological studies depression
Scale
x x x x x
Hospital anxiety and depression scale
(Depression)
- x x x x
Penn state worry questionnaire - x x x x
Behavioural activation depression scale - x x x x
Social problem solving inventory - Revised - x x x x
Haemoglobin A1c - x x x
Problem areas in diabetes - x x x x
Acceptance and action diabetes questionnaire - x x x x
Diabetes self-management questionnaire - x x x x
Kessler psychological distress scale - x - - -
Negative effects of online health trainings - - (x) - -
Attitudes towards seeking psychological help
scale
- x x - -
Measurements for the economic evaluation
Trimbos/iMTA questionnaire for costs associated
with Psychiatric Illness
- x - x x
Quality of life (EuroQol, SF-12) - x x x x
Additional measurements
Demographic variables questionnaire x - - - -
Lifestyle data x - - - -
Data on diabetes x - - - -
Patient questionnaire on therapy expectation and
evaluation (Online-Training)
- x - - -
Client Satisfactory Questionnaire - - (x) - -
Way of recruitment and familiarity with the
Internet
x - - - -
T0 Screening, T1 Baseline, T2 8 weeks, T3 6 months, T4 12 months.
Assessments: x = intervention and control group, (x) = intervention group only.Secondary outcome measures
The secondary outcome measures include the depression
subscale of the Hospital Anxiety and Depression Scale
(HADS [66,67]); the Penn State Worry Questionnaire
(PSWQ [68], 3-item short version [69]); the Behavioural
Activation Depression Scale (BADS [70], 9-item short ver-
sion [71]); the Social Problem Solving Inventory-Revised
(SPSI-R [72]); the long-term blood sugar level (self-re-
ported haemoglobin A1c values (HbA1c)); the Problem
Areas in Diabetes questionnaire (PAID [73], German
5-item short version [74]); the Acceptance and Action
Diabetes Questionnaire (AADQ [75], German version [76]);
the Diabetes Self-Management Questionnaire (DSMQ [77]);
the negative effects of online health trainings questionnaire
([78], self-adapted version for online health trainings);
the Kessler Psychological Distress Scale (K10 [79]); and
the Attitudes Towards Seeking Psychological Help Scale
(ATSPHS, [80], 10-item short version [81]).
Additional measurements
We will collect socio-demographic data (age, gender,
education and occupation); lifestyle data (body mass
index, smoking and alcohol use); data on diabetes (type,
duration of illness and comorbidity); Patient Question-
naire on Therapy Expectation and Evaluation (PATHEV
[82]); data on satisfaction with the program (a self-
designed questionnaire based on the German version of
the Client Satisfaction Questionnaire [83,84]); data about
the method of recruitment (for example through a dia-
betes journal or Facebook) and additional information
about the participant’s familiarity with the Internet.
Measurements for the economic evaluation
Cost measures
We will use the Dutch Cost Questionnaire “Trimbos
Institute and Institute of Medical Technology Question-
naire for Costs Associated with Psychiatric Illness”
(TiC-P) [85] adapted for the German health care sys-
tem. We will include the costs of any type of health care
and medicines (direct medical costs), travel expenses
and also those for parking (direct non-medical costs),
and the costs related to production losses (indirect
costs) [86].
Quality of life
Quality-adjusted life years (QALYs) will be calculated
based on the EuroQol (EQ-5D) [87] and the Short Form
Health Survey 12 (SF-12) [88]. The EQ-5D is a validated
tool for measuring general health-related quality of life.
It consists of five items (mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression), each of
which is rated as causing “no problems”, “some prob-
lems” or “extreme problems” [89]. Moreover, to generate
the QALYs, a visual analogue scale (VAS) ranging from
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health state) is also an integral part of the EQ-5D.
The SF-12 is based on the 36-item Short Form Health
Survey (SF-36), a health-related quality-of-life question-
naire [90]. The SF-12 focuses on eight dimensions of
health (physical functioning, role-physical, bodily pain,




The analysis will be performed according to the Consoli-
dated Standards of Reporting Trials (CONSORT) state-
ment regarding eHealth [91]. The data will be analysed
on an intention-to-treat (ITT) basis. Group differences
in the baseline values of the primary outcome will be
compared using t tests to assess whether randomisation
was successful. Missing data will be addressed following
the recommendations of Little and Rubin [92] and Schafer
[93]. We will analyse the CES-D data at two months post-
treatment using between-group analyses of covariance
(ANCOVAs) on the individual baseline depression scores,
adjusting for sex, age and socio-economic status. We will
use Cohen’s d to measure the between-group effect size.
Cohen’s d will be calculated as the difference between the
mean post-test scores of the intervention group and the
control group divided by the pooled standard deviation
[94]. All of the other secondary outcomes will be analysed
in the similar way.
We will also conduct clinical significance change ana-
lyses as described by Jacobson and Truax [95,96]. In the
first step, we will test whether the changes from pre-test
to post-test are statistically reliable and build a reliable
change index (RCI). In the second step, we will calculate
the clinical significance. Based on the reliable change
index, the participants who display a reliable positive
change, no change or a reliable deteriorated change will
be classified as responders, non-responders or deterio-
rated, respectively [95].
As secondary analyses, we will also conduct per-
protocol (PP) and completers-only analyses.
To show the long-term effect on the primary outcome
after 6 months and 12 months, we will use mixed models.
Economic evaluation
The economic analysis will be performed from a societal
perspective. We will conduct a cost-effectiveness analysis
(CEA) and a cost-utility analysis (CUA). Using the incre-
mental cost-effectiveness ratio (ICER), we will show the
differences in the costs and benefits between the two
groups. The robustness of the ICER will be determined
using non-parametric bootstrapping. Furthermore, we
will also use bootstrapping to quantify the uncertainty
around the ICER, which will be shown on the cost-effectiveness plane [97] and as a cost-effectiveness
acceptability curve [98,99]. To perform the CUA, we cal-
culate QALYs from the EQ-5Q and also from the SF-12.
Discussion
In the present study, we aim to compare a web-based pro-
gram with mobile phone support and minimal guidance
with a control group, receiving psychoeducation only. We
expect the depression level of the participants in the inter-
vention group to be significantly lower immediately after
the intervention and also after 6 and 12 months compared
with the control group. Our planned analyses will enable
us to assess whether the outcomes are sustained over time.
Depressive symptoms in people with diabetes have an
adverse impact on mental health, quality of life and on
medical outcomes such as blood glucose [3-7]. Com-
pared to the comprehensive body of evidence concern-
ing web-based interventions for depression, very little is
known about the efficacy of web-based interventions in
persons with comorbid (somatic) disorders. This study
will contribute to the evaluation of evidence concerning
web-based interventions for participants with diabetes
and co-morbid depression.
Depression treatments for adults with diabetes pro-
duce economic benefits [100]. Until now, there has been
no evidence about the cost-effectiveness of web-based
treatments for diabetes with comorbid depression. We
will conduct CEA und CUA from a societal perspective.
If the intervention is cost-effective, these findings may
encourage the health care system (including health in-
surance companies) to integrate those web-based pro-
grams into routine diabetes care.
Because adherence to recommendations involving
treatment recommendations and lifestyle changes is
often a problem with diabetes patients [35], depressive
people [36,37] and with participants in web-based inter-
ventions [38], we will use two methods to improve the
efficacy of the intervention by increasing the number of
sessions completed by the intervention group. Firstly, all
of the participants can receive daily text message sup-
port [61-64]. Secondly, all of the participants who have
not logged in to the program seven days after an email
reminder will be contacted by their trainer by phone
[65]. The trainer will then try to motivate the participant
to continue with the intervention. We decided to focus
on these two methods; however there are other ap-
proaches such as the concept of persuasive technology
[101]. It is unknown which methods should be recom-
mended, so further studies should examine which ones
are effective concerning web-based interventions.
Limitations
One limitation of this study design is that many diabetes
patients are elderly, especially those with diabetes type 2
Nobis et al. BMC Psychiatry 2013, 13:306 Page 8 of 10
http://www.biomedcentral.com/1471-244X/13/306and may have limited access to the Internet. In 2002,
only 8% of the Germans 60 or older had access to the
Internet: this number increased to 39% ten years later
[102]. The results from this study cannot be generalised
to the overall population of patients with diabetes (espe-
cially type 2) and comorbid depression.
Furthermore, it is known that lower social status and
lower education are associated with an increased risk for
diabetes [103] and that women (28%) have significantly
higher rates of depression compared to men (18%) [2]. As
studies show, web-based interventions are mostly used by
higher educated persons and females [32,104,105]. There-
fore, we expect selection bias, restricting the external
validity, particularly with regard to lower educated and
males with diabetes.
Conclusions
Given the high prevalence of comorbid diabetes and
depression, web-based interventions may have great po-
tential to lower the threshold and increase access to the
treatment of these co-morbid disorders. If GET.ON M.
D. is shown to be cost- effective, it has great potential to
be integrated into routine care and so to improve the
well-being of people with diabetes and comorbid depres-
sion. This is of high importance given the negative im-
pact of co-occurrence of diabetes and depression on
psychological and medical outcomes, as well as on the
health care system [3-7,10,12,14,100].
Further research is necessary to establish whether
interventions that integrate diabetes and depression are
more effective in the long term compared with conven-
tional depression interventions.
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